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ANTICONVULSANT DRUGS. Volume 1. International Encyclopedia of Pharmacology
and Therapeutics, Section 19, J. Mercier (Section editor); Pergamon Press, Oxford,
1973. 402 pp. $28.50.
This volume is the first half of the anticonvulsant drug section of the I.E.P.T.,
which is sponsored by the International Union of Pharmacology and is intended to
provide comprehensive compendia of basic and clinical information about major
drug groups. In general, the goal is achieved here. The latter half of the book con-
sists of four excellent chapters on laboratory-clinical correlations, structure-
activity relationships, and pharmacokinetics in animals and man. These chapters
are densely referenced, for the most part well organized, and contain adequate his-
torical perspective; together they constitute a valuable reference for phar-
macologists and clinicians. The book's first four chapters are less satisfactory. The
first of these is a review of the classification and presumed pathophysiology of
epileptic seizures. The material presented is all available elsewhere, and much of it
has been published repeatedly. One can question whether any useful purpose is
served by presenting it again in. a pharmacological reference work which is likely to
be used most by people who have more extensive treatment of these subjects ready
at hand. The three succeeding chapters on methods for assessing anticonvulsant
activity of drugs are too long; one of them is filled with unpublished personal data
and rambling discussions ofmatters remote from pharmacology.
This volume covers much of the same ground as Antiepileptic Drugs, Woodbury,
et al. (eds.) and Experimental Models ofEpilepsy, Purpura et al. (eds.). However,
there is enough difference in content that a research worker in this area will want ac-
cess to all three books. A clinician in need of a single work for occasional reference




THE PERSECUTED DRUG. THE STORY OF DMSO. By Pat McGrady, Sr. Doubleday
and Co., New York, 1973. viii, 372 pp. $7.95.
An inexpensive panacea repressed by a federal agency, a selfless dedicated phy-
sician dedicated to his patients. There are theingredients ofa book on the recent for-
tunes ofdimethylsulfoxide. There are good guys (physicians), bad guys (the govern-
ment, FDA), losers (patients), and winners (big business). The roles are as rigidly
defined as in a Hollywood western but that is not to say that westerns are not
entertaining. They are, and so is the book by Pat McGrady, a good story teller who
was the science editor of the American Cancer Society. His metier is the essay-the
short exposition, and the book would probably be best enjoyed as a series of inter-
rupted readings? The book is divided into five sections. These divisions do not reflect
any obvious attempt at organization in theusual sense; however, each ofthe five sec-
tions is lively, entertaining, and can be read as a free-standing essay. The book is less
than the sum of its five parts. The only theme that integrates the parts are the too
obvious type-cast roles described earlier. In the words of the author Pat McGrady
(adjectives his) ". . . the purchaser ofthis book gets not a single, simple, straightfor-
ward account of a drug but three stories in one: the incredible performance ofan un-
believable drug; the unlikely adventures of a fantastic government agency; and the162 BOOK REVIEWS
problems ofa man so good in a wicked world that his virtues are regarded as vices."





SELECTIVE TOXICITY (Fifth Edition). By Adrien Albert. Chapman and Hall
(London), 1973. 597 pages. $19.75.
Selective Toxicity is an exposition of the many chemical and biological principles
that allow drugs to act selectively. To incorporate both pharmacodynamics and
chemotherapy into the discussion, a rather broad definition of"selective toxicity" is
adopted ..."the injury of one kind of living matter without harming another
kind...."); thus propranolol is viewed as a reversible antagonist (injurer) of
A-receptors and penicillin as an irreversible injurer of gram-positive bacteria.
Chapters are built around the mechanisms of and principles behind selectivity, and
examples are chosen from past and present pharmacopoeias to illustrate the reduc-
tion of theory to practice. For instance, the penicillins are discussed in the chapters
on comparative cytology (structure of bacterial cell walls), principles of che-
motherapy (problem of resistant organisms), covalent bonds (details ofacylation of
cell wall components), and steric factors (reactivity ofthe,3-lactam ring).
Albert's writing is crisp and remarkably jargon-free. The readability ofSelective
Toxicity is commendable, but occasionally mechanisms are summarized too
tersely, neatly, and uncritically, and the novice may be led to believe that drugs are
more selective than they really are. Cardiac glycosides are said to have a "direct and
selective action on heart muscle"; no discussion of their neurotoxic side effects ap-
pears. Chloramphenicol is said to "specifically inhibit protein synthesis in bacterial
ribosomes"; the occasional action on human bone marrow leading to aplastic
anemia is not mentioned. As for drug design gone awry, thalidomide's teratogenic
action is only mentioned once, in passing, in one sentence in the book.
Specialists and careful readers will find a few technical errors in the text. Notable
ones occur in the discussion of Lineweaver-Burk plots (Km is not "shown at the in-
tersection of slope and ordinate") and in the chapter on steric factors (after a lucid
discussion of the rectus/sinister convention, the structures of ephedrine and
pseudoephedrine are drawn correctly, but the configurations are misassigned).
Selective Toxicity is not a comprehensive treatment ofeither medicinal chemistry
or pharmacology and cannot be recommended as the principal text in a course in
either discipline. But selected chapters are highly recommended as stimulating sup-
plementary reading. Albert's book illustrates, over and over again, how seemingly
irrelevant work in organic chemistry and comparative biochemistry can lead to
medical advances. In an era ofdiminished funds for basic research, this point cannot
be made too often.
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